vs
Side-by-side financial comparison of STRATA Skin Sciences, Inc. (SSKN) and SWK Holdings Corp (SWKH). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $8.7M, roughly 1.1× SWK Holdings Corp). On growth, STRATA Skin Sciences, Inc. posted the faster year-over-year revenue change (-3.0% vs -29.7%). SWK Holdings Corp produced more free cash flow last quarter ($26.8M vs $-551.0K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -12.5%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
SWK Holdings Corp is a specialty finance firm focused on the healthcare and life sciences sectors. It provides tailored financing solutions including royalty monetization, structured debt, and asset-backed lending to biotech, pharmaceutical, medical device and diagnostic companies, with its core market centered in North America.
SSKN vs SWKH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.3M | $8.7M |
| Net Profit | $58.0K | $-19.4M |
| Gross Margin | 61.8% | — |
| Operating Margin | 5.3% | 9.9% |
| Net Margin | 0.6% | — |
| Revenue YoY | -3.0% | -29.7% |
| Net Profit YoY | 101.3% | -430.2% |
| EPS (diluted) | $0.14 | $-1.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.3M | $8.7M | ||
| Q3 25 | $6.9M | $10.9M | ||
| Q2 25 | $7.7M | $10.1M | ||
| Q1 25 | $6.8M | $11.8M | ||
| Q4 24 | $9.6M | $12.4M | ||
| Q3 24 | $8.8M | $10.4M | ||
| Q2 24 | $8.4M | $10.8M | ||
| Q1 24 | $6.8M | $11.4M |
| Q4 25 | $58.0K | $-19.4M | ||
| Q3 25 | $-1.6M | $8.8M | ||
| Q2 25 | $-2.6M | $3.5M | ||
| Q1 25 | $-2.1M | $4.5M | ||
| Q4 24 | $-4.6M | $5.9M | ||
| Q3 24 | $-2.1M | $3.5M | ||
| Q2 24 | $-91.0K | $3.7M | ||
| Q1 24 | $-3.4M | $468.0K |
| Q4 25 | 61.8% | — | ||
| Q3 25 | 60.4% | — | ||
| Q2 25 | 56.2% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 61.4% | — | ||
| Q3 24 | 60.1% | — | ||
| Q2 24 | 59.0% | — | ||
| Q1 24 | 45.6% | — |
| Q4 25 | 5.3% | 9.9% | ||
| Q3 25 | -16.9% | 61.3% | ||
| Q2 25 | -30.1% | 46.1% | ||
| Q1 25 | -25.0% | 68.6% | ||
| Q4 24 | -44.7% | 44.7% | ||
| Q3 24 | -18.2% | 39.2% | ||
| Q2 24 | -5.7% | 8.3% | ||
| Q1 24 | -42.7% | 9.5% |
| Q4 25 | 0.6% | — | ||
| Q3 25 | -23.4% | 80.7% | ||
| Q2 25 | -33.6% | 35.2% | ||
| Q1 25 | -31.2% | 38.4% | ||
| Q4 24 | -47.6% | 47.5% | ||
| Q3 24 | -23.6% | 33.3% | ||
| Q2 24 | -1.1% | 33.9% | ||
| Q1 24 | -49.8% | 4.1% |
| Q4 25 | $0.14 | $-1.59 | ||
| Q3 25 | $-0.36 | $0.72 | ||
| Q2 25 | $-0.62 | $0.29 | ||
| Q1 25 | $-0.51 | $0.37 | ||
| Q4 24 | $-2.01 | $0.47 | ||
| Q3 24 | $-0.51 | $0.28 | ||
| Q2 24 | $-0.03 | $0.30 | ||
| Q1 24 | $-0.10 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.9M | $42.8M |
| Total DebtLower is stronger | $15.3M | $33.0M |
| Stockholders' EquityBook value | $2.9M | $235.1M |
| Total Assets | $30.5M | $272.4M |
| Debt / EquityLower = less leverage | 5.28× | 0.14× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.9M | $42.8M | ||
| Q3 25 | $7.1M | $10.2M | ||
| Q2 25 | $6.0M | $8.0M | ||
| Q1 25 | $6.5M | $29.8M | ||
| Q4 24 | $7.3M | $5.9M | ||
| Q3 24 | $7.1M | $17.2M | ||
| Q2 24 | $5.5M | $5.5M | ||
| Q1 24 | $5.2M | $5.5M |
| Q4 25 | $15.3M | $33.0M | ||
| Q3 25 | $15.3M | $33.0M | ||
| Q2 25 | $15.0M | $33.0M | ||
| Q1 25 | $15.0M | $33.0M | ||
| Q4 24 | $15.0M | $33.0M | ||
| Q3 24 | $15.0M | $33.0M | ||
| Q2 24 | $15.0M | $33.0M | ||
| Q1 24 | $15.0M | $33.0M |
| Q4 25 | $2.9M | $235.1M | ||
| Q3 25 | $1.3M | $254.2M | ||
| Q2 25 | $532.0K | $246.5M | ||
| Q1 25 | $3.0M | $292.7M | ||
| Q4 24 | $5.0M | $288.7M | ||
| Q3 24 | $9.4M | $283.4M | ||
| Q2 24 | $9.5M | $282.8M | ||
| Q1 24 | $9.4M | $279.9M |
| Q4 25 | $30.5M | $272.4M | ||
| Q3 25 | $30.7M | $289.4M | ||
| Q2 25 | $29.5M | $285.7M | ||
| Q1 25 | $33.0M | $331.3M | ||
| Q4 24 | $34.9M | $332.2M | ||
| Q3 24 | $39.4M | $321.3M | ||
| Q2 24 | $38.8M | $321.0M | ||
| Q1 24 | $39.2M | $322.0M |
| Q4 25 | 5.28× | 0.14× | ||
| Q3 25 | 11.65× | 0.13× | ||
| Q2 25 | 28.20× | 0.13× | ||
| Q1 25 | 5.04× | 0.11× | ||
| Q4 24 | 3.02× | 0.11× | ||
| Q3 24 | 1.60× | 0.12× | ||
| Q2 24 | 1.58× | 0.12× | ||
| Q1 24 | 1.59× | 0.12× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-239.0K | $27.3M |
| Free Cash FlowOCF − Capex | $-551.0K | $26.8M |
| FCF MarginFCF / Revenue | -5.9% | 308.1% |
| Capex IntensityCapex / Revenue | 3.4% | 5.9% |
| Cash ConversionOCF / Net Profit | -4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | $43.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-239.0K | $27.3M | ||
| Q3 25 | $-64.0K | $906.0K | ||
| Q2 25 | $-1.9M | $7.8M | ||
| Q1 25 | $-550.0K | $8.3M | ||
| Q4 24 | $703.0K | $23.0M | ||
| Q3 24 | $-302.0K | $6.3M | ||
| Q2 24 | $591.0K | $5.4M | ||
| Q1 24 | $-804.0K | $4.4M |
| Q4 25 | $-551.0K | $26.8M | ||
| Q3 25 | $-1.1M | $557.0K | ||
| Q2 25 | $-2.0M | $7.7M | ||
| Q1 25 | $-749.0K | $8.2M | ||
| Q4 24 | $199.0K | $22.9M | ||
| Q3 24 | $-364.0K | $6.3M | ||
| Q2 24 | $246.0K | $5.4M | ||
| Q1 24 | $-1.5M | — |
| Q4 25 | -5.9% | 308.1% | ||
| Q3 25 | -15.6% | 5.1% | ||
| Q2 25 | -26.1% | 77.0% | ||
| Q1 25 | -11.0% | 69.1% | ||
| Q4 24 | 2.1% | 185.3% | ||
| Q3 24 | -4.1% | 60.4% | ||
| Q2 24 | 2.9% | 49.7% | ||
| Q1 24 | -22.6% | — |
| Q4 25 | 3.4% | 5.9% | ||
| Q3 25 | 14.7% | 3.2% | ||
| Q2 25 | 0.8% | 0.6% | ||
| Q1 25 | 2.9% | 0.8% | ||
| Q4 24 | 5.3% | 1.1% | ||
| Q3 24 | 0.7% | 0.3% | ||
| Q2 24 | 4.1% | 0.2% | ||
| Q1 24 | 10.7% | 0.0% |
| Q4 25 | -4.12× | — | ||
| Q3 25 | — | 0.10× | ||
| Q2 25 | — | 2.21× | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 3.93× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | 1.47× | ||
| Q1 24 | — | 9.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
SWKH
| Finance Receivables Segment | $8.4M | 96% |
| Other | $329.0K | 4% |
